Effect of lazabemide on the progression of disability in early Parkinson's disease

Annals of Neurology

Volumn 40, Issue 1, 1996, Pages 99-107

  Kieburtz, Karl ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAZABEMIDE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TABLET; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PICOLINIC ACIDS; TREATMENT OUTCOME;

EID: 0029927070     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400116     Document Type: Article

References (22)

1. Da Prada M, Kettler R, Keller HH, et al. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 1990;29(suppl):279-292
2. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of MPTP in monkeys. Eut J Pharmacol 1984;106:209-210
3. Reinhard F Jr, Carmichael SW, Daniels AJ. Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. J Neurochem 1990;55: 311-320
4. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
5. Teravainen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990;81:333-336
6. Allain H, Cougnard J, Neukrich H-C, the FSMT members. Selegiline in de novo parkinsonian patients: the French Selegiline Multicenter Trial (FSMT). Acta Neurol Scand Suppl 1991;136:73-78
7. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992;42:339-343
8. DaPrada M, Kettlet R, Keller HH, Burkard WP. Ro 19-6327, a reversible, highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine-potentiating effects: comparison with selegiline. In: Dahlstrom A, ed. Progress in catecholamine research. Part B: central aspects. New York: Alan R Liss, 1988:359-363
9. Bench CJ, Price GW, Lammertsma AA, et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991;40:169-173
10. Fowler JS, Bolkow ND, Logan J, et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19-6327. Neurology 1993;43:1984-1992
11. Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in untreated Parkinson's disease. Ann Neurol 1993; 33:350-356
12. Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Arch Neurol 1994;51:342-347
13. Hoehn MM, Yahr MD. Parkinsonisnr: onset, progression and mortality. Neurology 1967;17:427-442
14. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:285-309
15. Folstein MF, Folstein SE, McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
17. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220
18. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34:585-612
19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980
20. Kaplan EL, Meier P. Nonparamerric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
21. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-245
22. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672